Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Virginia
The current proposal seeks to apply and extend this novel genomic prediction technique to finding better chemotherapeutic options for recurrent ovarian cancer using individual patients' gene-expression signatures of chemosensitivity. The utility of the COXEN technique has been validated and found to accurately predict 1) the chemosensitivity of an independent panel of 40 bladder cancer cell lines; 2) activity of each of the \>45K candidate compounds in the NCI-60 drug screening database, which resulted in the identification of a highly-effective novel compound for bladder cancer and patients' responses and survival on 12 historical clinical trials of combination chemotherapy. In particular, the GEMs of breast cancer can be used to stratify both clinical response and overall patient survival with a striking difference between the predicted responders vs. predicted non-responders in 5 independent chemotherapeutic trials of breast cancer. The next step is to test the prediction model in recurrent ovarian cancer.
Age
18–95
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
age greater than 18
diagnosis of recurrent, persistent, refractory ovarian, fallopian or primary peritoneal cancer
tumor tissue, ascites or pleural fluid available for biopsy
life expectancy greater than 6 months
You may not be if
patients with borderline or low malignant histologies
patients with a history of other malignancies within last 5 years